Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.

Summary

Loss of bone mass is a common complication in patients with end-stage-renal failure, both before and particularly after transplantation. In addition to standard underlying therapy with calcium and active vitamin D, we will study the effect of ibandronate (a bisphosphonate) versus placebo on bone mineral density as well as incidence of fracture rates after kidney transplantation.We also wish to study whether any prevented bone loss will also lead to reduced cardiovascular disease. Patients will be followed for 12 months after transplantation, and the ibandronate treatment is one injection every 3 months.

Timeline

Start

2007-01

Primary completion

2009-12

Completion

2010-12

Publications

• Strommen RC, Godang K, Hovd MH, Finnes TE, Smerud K, Hartmann A, Asberg A, Bollerslev J, Pihlstrom HK. Hip geometry and strength remain stable the first year after kidney transplantation-an ibandronate/placebo post hoc analysis. JBMR Plus. 2024 Oct 24;8(12):ziae130. doi: 10.1093/jbmrpl/ziae130. eCollection 2024 Dec.

Drugs

Indications

No indication recorded.